



Docket No. 50229-194

OCT 01 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kenneth B. AIN, et al.

Serial No.: 09/606,042

Filed: June 29, 2000

Group Art Unit: 1642
Examiner: S.L. RAWLINGS

1600
RECEIVED
OCT 04 2002
TECH CENTER 1600/2900

For: IODIDE UPTAKE RESTORATION IN THYROID CANCER

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231

Dear Sir:

Transmitted herewith is an Amendment in the above identified application.



No additional fee is required.



Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.



A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.



Also attached:

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	17	20	0	\$18.00 =	\$0.00
Independent Claims	3	3	0	\$84.00 =	\$0.00
Multiple claims newly presented					\$0.00
Fee for extension of time					\$0.00
Total of Above Calculations					\$0.00



Please charge my Deposit Account No. 50-0417 in the amount \$ ____ . An additional copy of this transmittal sheet is submitted herewith.



The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 500417, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

McDERMOTT WILL & EMERY

Judith L. Toffenetti
Registration No. 39,048

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 RLP/JLT/rp
Date: October 1, 2002
Facsimile: (202) 756-8087



Attorney Docket No.: 56229-194

RECEIVED
PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Kenneth B. AIN, et al.

Serial No.: 09/606,042

Filed: June 29, 2000

For: IODIDE UPTAKE RESTORATION IN THYROID CANCER

: Attn: BOX AF

: Group Art Unit: 1642

: Examiner: Rawlings, S.L.

16/D
KD
10/8/02

AMENDMENT UNDER 37 C.F.R. § 1.116

Hon. Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the final Office Action mailed July 2, 2002, having a shortened statutory period for response set to expire October 2, 2002, please amend the subject application as follows:

IN THE CLAIMS:

Please amend claims 1 and 16 as follows:

Claim 1 (Twice Amended). A method of expressing a thyroid specific therapeutic response element in a human cancerous thyroid cell in which transcription of the gene encoding the response element and iodine transport into the cancerous cell was inhibited, comprising the step of administering an unblocking agent to the cancerous thyroid cell, thereby resulting in the expression of the response element and

SR 3/24/03
DO NOT
ENTER
SR 12/3/02

D1